Traditional Chinese medicine is the material basis for
the inheritance and innovation of traditional Chinese medicine.
In recent years, under the joint promotion of relevant departments, the Chinese medicine industry has shown a good development trend
.
National pharmaceutical industry statistics show that in the first half of 2022, the traditional Chinese medicine industry achieved steady growth, with revenue reaching 340.
7 billion yuan, an increase of 7.
7%
year-on-year.
Among them, the revenue of proprietary Chinese medicines was 240.
2 billion yuan, an increase of 6.
9% over the first half of 2021; The revenue of Chinese medicine tablets was 100.
5 billion yuan, an increase of 6.
9%
year-on-year.
In the first half of 2022, the total profit of the Chinese medicine industry was 40.
45 billion yuan, an increase of 6.
8%
year-on-year.
Among them, the total profit of proprietary Chinese medicines was 32.
57 billion yuan, an increase of 3.
4% over the first half of 2021; The total profit of Chinese medicine tablets was 7.
88 billion yuan, up 20.
3%
year-on-year.
It can be seen from the data that the performance of Chinese medicine tablets is particularly eye-catching, both revenue and net profit have achieved double growth, and the total net profit has increased significantly compared with the same period last year, which is far more than the year-on-year growth value
of 3.
4% of proprietary Chinese medicines.
Chinese medicine tablets for one of the three pillars of China's traditional Chinese medicine industry, with the intensification of population aging, the cultivation of Chinese herbal medicines in China and the promotion of traditional Chinese medicine tablets are increasing year by year, while the tablet industry is supported by the favorable policies of medical insurance, in accordance with the current "National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue (2021)", there are currently 892 kinds of Chinese medicine tablets have been included in the national medical insurance drug catalog
.
Under the resonance of multiple factors, the market expansion of traditional Chinese medicine tablets has been accelerating, and the number of entrants has also increased
.
According to the "2021 Blue Book of National Chinese Medicine Supervision", by the end of 2021, there are 2225 proprietary Chinese medicine manufacturers and 2023 Chinese medicine tablets manufacturers in China
.
The quality of Chinese medicine tablets is constantly improving
.
For a long time, Chinese medicine tablets have become "regulars" who fail to pass the sampling inspection due to the backward standards of some Chinese medicinal materials, the unscientific cultivation of traditional Chinese medicines, the large number of small workshops with low prices and low quality, and the difficulty of accurate supervision
.
In order to improve the quality of drinking tablets, in recent years, with the continuous efforts of relevant departments, the production quality of Chinese herbal medicines has been continuously improved
.
The 2021 National Drug Sampling Annual Report of the State Food and Drug Administration shows that the total pass rate of sampling of Chinese medicine tablets has reached 98%.
In order to further standardize the development of the Chinese medicine tablet industry, since 2022, China has also successively introduced a series of new policies and new regulations to boost the industry towards the road of high quality
.
For example, on July 8, the State Food and Drug Administration issued the "Regulations on the Administration of Packaging Labels for Chinese Medicine Tablets (Draft for Solicitation of Comments)" to further standardize the management of packaging labels for Chinese medicine tablets; In March, the State Food and Drug Administration, together with the Ministry of Agriculture and Rural Affairs, the State Administration of Traditional Chinese Medicine and other departments, completed the revision and promulgation
of the "Good Manufacturing Practice for Chinese Materia Medica".
At present, Jicai is the sword of Damocles hanging over the head of the Chinese medicine tablet industry, before which the provincial alliance led by Fenghua District of Ningbo City, Zhejiang Province, Anhui Province, and Shandong Province has issued documents to carry out pilot collection, and the varieties of collection are mostly Sichuan root, raw yellow, melon seeds, astragalus, party ginseng pieces, honeysuckle and a large number of common drinking tablets
.
In addition, the recent "National Proprietary Chinese Medicine Alliance Procurement Announcement" has been released, and the document clarifies that 30 provinces (excluding Hunan, Fujian, Hong Kong, Macao and Taiwan) will form a national joint procurement office for proprietary Chinese medicines, led
by the Hubei Medical Insurance Bureau.
The industry believes that the collection of procurement through the exchange of price for volume, or to the entire tablet industry to bring a big reshuffle, but in the long run is conducive to the improvement
of industry concentration.
